Combination of the anti-CD30-auristatin-E antibody-drug conjugate SGN-35 with chemotherapy improves antitumor activity in Hodgkin's lymphoma

被引：0
|
作者：
Oflazoglu, E. [1 ]
Kennedy, D. [2 ]
Sievers, E. L. [2 ]
Kissler, K. M. [1 ]
Jonas, M. [3 ]
Ihle, N. C. [4 ]
Grewal, I. S. [1 ]
Gerber, H. [1 ]
机构：
[1] Seattle Genet Inc, Preclin Therapeut, Bothell, WA USA
[2] Seattle Genet Inc, Clin, Bothell, WA USA
[3] Seattle Genet Inc, Antibody Technol, Bothell, WA USA
[4] Seattle Genet Inc, Proc Chem, Bothell, WA USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：235 / 236
页数：2
相关论文
共 50 条
  • [1] Combination of the anti-CD30-auristatin-E antibody-drug conjugate SGN-35 with chemotherapy improves antitumor activity in Hodgkin lymphoma
    Gerber, H. P.
    Oflazoglu, E.
    Kissler, K.
    Kennedy, D.
    Sievers, E. L.
    Ihle, N. C.
    Meyer, D. L.
    Grewal, I. S.
    EJC SUPPLEMENTS, 2008, 6 (12): : 166 - 166
  • [2] Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma
    Oflazoglu, Ezogelin
    Kissler, Kim M.
    Sievers, Eric L.
    Grewal, Iqbal S.
    Gerber, Hans-Peter
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 142 (01) : 69 - 73
  • [3] SGN-35, an anti-CD30 antibody-drug conjugate, exhibits potent antitumor activity for the treatment of CD30+ malignancies.
    Hamblett, KJ
    Barton, J
    Cerveny, CG
    Andreyka, JB
    Kissler, KM
    Okeley, NM
    Stone, I
    Sutherland, MK
    Sun, MM
    Senter, PD
    Wahl, AF
    Ihle, NC
    BLOOD, 2005, 106 (11) : 181A - 181A
  • [4] Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
    Okeley, Nicole M.
    Miyamoto, Jamie B.
    Zhang, Xinqun
    Sanderson, Russell J.
    Benjamin, Dennis R.
    Sievers, Eric L.
    Senter, Peter D.
    Alley, Stephen C.
    CLINICAL CANCER RESEARCH, 2010, 16 (03) : 888 - 897
  • [5] The anti-CD30 antibody-drug conjugate SGN-35 is a potent therapy for the treatment of CD30+malignancies
    Barton, J
    Hamblett, K
    Cerveny, C
    Andreyka, J
    Kissler, K
    Stone, I
    Sun, M
    Senter, P
    Wahl, A
    Francisco, J
    Ihle, N
    ANNALS OF ONCOLOGY, 2005, 16 : 134 - 134
  • [6] A novel antibody-drug conjugate, SGN-35 (anti-CD30-auristatin), induces objective responses in patients with relapsed or refractory Hodgkin lymphoma: preliminary results of a phase I tolerability study
    Younes, A.
    Forero-Torres, A.
    Bartlett, N.
    Leonard, J. P.
    Rege, B.
    Kennedy, D. A.
    Lorenz, J.
    Sievers, E. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 64 - 64
  • [7] ACTIVITY, SAFETY AND TOLERABILITY OF ANTIBODY-DRUG CONJUGATE (ADC) SGN-35 IN RELAPSED/REFRACTORY (R/R) HODGKIN LYMPHOMA (HL) AND CD30+ HEMATOLOGIC MALIGNANCIES
    McCarty, J. M.
    Sureda, A.
    Sweetenham, J.
    Moskowitz, C. H.
    Kennedy, D.
    Sievers, E. L.
    HAEMATOLOGICA, 2010, 95 : S28 - S28
  • [8] Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies
    Gualberto, Antonio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (02) : 205 - 216
  • [9] Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate (vol 16, pg 888, 2010)
    Okeley, N. M.
    Miyamoto, J. B.
    Zhang, X.
    Sanderson, R. J.
    Benjamin, D. R.
    Sievers, E. L.
    CLINICAL CANCER RESEARCH, 2011, 17 (16) : 5524 - 5524
  • [10] Specific tumor targeting and potent bystander killing with SGN-35, an anti-CD30 antibody drug conjugate.
    Okeley, Nicole M.
    Alley, Stephen C.
    Cerveny, Charles G.
    Andreyka, Jamie
    Sanderson, Russell J.
    Anderson, Martha
    Benjamin, Dennis R.
    Law, Che-Leung
    Sievers, Eric
    Ihle, Nathan C.
    BLOOD, 2006, 108 (11) : 72A - 72A
12345